These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26634942)

  • 41. Vaginal hormone-free moisturising cream is not inferior to an estriol cream for treating symptoms of vulvovaginal atrophy: Prospective, randomised study.
    Garcia de Arriba S; Grüntkemeier L; Häuser M; May TW; Masur C; Stute P
    PLoS One; 2022; 17(5):e0266633. PubMed ID: 35551533
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaginal pH: a simple assessment highly correlated with vaginal morphology and symptoms in postmenopausal women.
    Tucker KM; Godha K; Mirkin S; Archer DF
    Menopause; 2018 Jul; 25(7):762-766. PubMed ID: 29509598
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravaginal 6.5 mg prasterone administration in postmenopausal women with overactive bladder syndrome: A pilot study.
    Matarazzo MG; Sarpietro G; Fiorito D; Di Pasqua S; Ingrassano S; Panella MM; Cianci A; Caruso S
    Eur J Obstet Gynecol Reprod Biol; 2021 Aug; 263():67-71. PubMed ID: 34167036
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of intravaginal dehydroepiandrosterone (DHEA) for symptomatic women in the peri- or postmenopausal phase.
    Sauer U; Talaulikar V; Davies MC
    Maturitas; 2018 Oct; 116():79-82. PubMed ID: 30244783
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women.
    Cruz VL; Steiner ML; Pompei LM; Strufaldi R; Fonseca FLA; Santiago LHS; Wajsfeld T; Fernandes CE
    Menopause; 2018 Jan; 25(1):21-28. PubMed ID: 28763401
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy.
    Freedman M; Kaunitz AM; Reape KZ; Hait H; Shu H
    Menopause; 2009; 16(4):735-41. PubMed ID: 19252451
    [TBL] [Abstract][Full Text] [Related]  

  • 47. What is the role of dehydroepiandrosterone in gynecologic practice?
    Gajarawala SN; Wood TA; Stanton AP
    JAAPA; 2019 Dec; 32(12):11-12. PubMed ID: 31770299
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women.
    Constantine GD; Bouchard C; Pickar JH; Archer DF; Graham S; Bernick B; Mirkin S
    J Womens Health (Larchmt); 2017 Jun; 26(6):616-623. PubMed ID: 28355090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The vagina as source and target of androgens: implications for treatment of GSM/VVA, including DHEA.
    Cipriani S; Maseroli E; Ravelli SA; Vignozzi L
    Climacteric; 2023 Aug; 26(4):309-315. PubMed ID: 37288964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of non-hormonal remedies for vaginal dryness: open, prospective, randomized trial.
    Stute P; May TW; Masur C; Schmidts-Winkler IM
    Climacteric; 2015; 18(4):582-9. PubMed ID: 25845406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
    Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.
    Simon JA; Goldstein I; Kim NN; Davis SR; Kellogg-Spadt S; Lowenstein L; Pinkerton JV; Stuenkel CA; Traish AM; Archer DF; Bachmann G; Goldstein AT; Nappi RE; Vignozzi L
    Menopause; 2018 Jul; 25(7):837-847. PubMed ID: 29870471
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ▼Prasterone for vulvar and vaginal atrophy.
    Drug Ther Bull; 2019 Dec; 57(12):185-188. PubMed ID: 31578208
    [No Abstract]   [Full Text] [Related]  

  • 54. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?
    Edwards D; Panay N
    Climacteric; 2016 Apr; 19(2):151-61. PubMed ID: 26707589
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravaginally applied oxytocin improves post-menopausal vaginal atrophy.
    Al-Saqi SH; Uvnäs-Moberg K; Jonasson AF
    Post Reprod Health; 2015 Sep; 21(3):88-97. PubMed ID: 25995333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
    McLendon AN; Clinard VB; Woodis CB
    Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G; Bobula J; Mirkin S
    Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prasterone (Intrarosa) for dyspareunia.
    Med Lett Drugs Ther; 2017 Sep; 59(1529):149-150. PubMed ID: 28880846
    [No Abstract]   [Full Text] [Related]  

  • 59. A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy.
    Bell RJ; Rizvi F; Islam RM; Davis SR
    Menopause; 2018 Jun; 25(6):704-709. PubMed ID: 29286987
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prasterone (Intrarosa) for Dyspareunia.
    Hayes R; Birch M
    Am Fam Physician; 2019 Jan; 99(2):117-122. PubMed ID: 30633482
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.